In this recent article, the Financial Times highlights Dr. Sherrif Ibrahim’s role in validating the DecisionDx-SCC test, developed by Castle Biosciences. This innovative tool significantly enhances the prediction of skin cancer spread, surpassing traditional methods that rely mainly on visual assessments and patient history. At the 56th American College of Mohs Surgery Annual Meeting, Dr. Ibrahim showcased the test’s ability …
In this recent article, Practical Dermatology highlights the growing importance of photodynamic therapy for treating a skin condition called actinic keratosis. Although photodynamic therapy is the top method for treating actinic keratosis, it can require multiple visits and may be uncomfortable. Dr. Sherrif Ibrahim, who brings both clinical experience and academic insight to his approach, explains how Rochester Dermatologic Surgery …
In this recent article, PRNewswire discusses how Sciton is improving its mJOULE system by adding new ways to treat blood vessels on the face, legs, or other parts of the body. This is a machine Dr. Sherrif Ibrahim helped develop and uses at Rochester Dermatologic Surgery to address various skin concerns. With the new update, Dr. Ibrahim looks forward to …
In this recent article, Medical Dialogues talks about Dr. Sherrif Ibrahim’s co-research on a new technology that can speed up skin cancer diagnosis. Nonmelanoma skin cancer is the most prevalent cancer in the United States, with more cases reported each year than all other types of cancer combined. To tackle this issue, Michael Giacomelli, a professor at the University of …
In this recent article, New You highlights how Dr. Sherrif Ibrahim is leading the way with Moxi, a laser treatment that promises red-carpet-worthy skin with just one session. Using Moxi, you can rejuvenate your skin by creating micro-injuries that target pigments in the top layers, resulting in an even tone and fewer brown spots. There is little downtime and no …
In this recent article, Practical Dermatology highlights Dr. Sherrif Ibrahim’s research on gene expression profiling of the second most common skin cancer, squamous cell carcinoma (SCC). “We worry about squamous cell carcinoma because occasionally it can misbehave and travel to other areas of the body like the lymph nodes in the neck, and then it can become life-threatening,” Dr. Ibrahim …
This recent article discusses Dr. Sherrif Ibrahim’s work in developing the new Moxi/BBL laser combination for skin rejuvenation. This powerful approach has revolutionized the treatment of uneven skin tone, roughness, and textural imperfections of the skin. The results speak for themselves. This article was featured in Modern Aesthetics. As patients want increasing improvement of their skin with less downtime and easier …
Although the rates for squamous cell carcinoma (SCC) spreading to other parts of the body are low, the overall incidence of the disease is high, making the number of SCC fatalities greater than that of melanoma. “While our current staging systems have improved risk prediction, we still need to get better at predicting which squamous cell carcinomas will metastasize,” says …
We are pleased to announce that both of our Mohs surgeons at Rochester Dermatologic Surgery are now double board-certified in Dermatology and Mohs Micrographic Surgery! Recent changes by the American College of Mohs Surgery (ACMS) have included offering a qualified fellowship-trained Mohs surgeons (already board-certified in Dermatology) to sit for an additional board exam specifically in Mohs Micrographic Surgery for …
In this press release, Dr. Sherrif Ibrahim comments on the utility of Castle Biosciences’ new gene expression profiling test for squamous cell carcinoma (SCC). We are seeing so many cases each day of SCC at Rochester Dermatologic Surgery. Although most of these cancers are cured easily in our office with surgery, we know that as many as 1 in 20 …
